IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA

IDEC Y2B8 放射免疫治疗 B 细胞非霍奇金淋巴瘤

• 批准号: 6304157
• 负责人: Leo I. Gordon
• 金额: $ 2.05万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304157
• 关键词: B lymphocyte; antineoplastics; clinical research; combination cancer therapy; human subject; human therapy evaluation; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; nonHodgkin's lymphoma; platelets; radiotracer

The current IDEC Pharmaceuticals protocol evaluating the efficacy and safety of IDEC-Y2B8 is a randomized study comparing Rituxan alone to Rituxan and radiolabelled monoclonal antibody therapy. It is restricted to patients who have platelet counts above 150,000. The proposed study IDEC 106-05 is a non-randomized study using Rituxan and IDEC Y2B8 for patients with platelet counts from 100-150,000.

IDEC Pharmaceuticals评价IDEC-Y2 B8疗效和安全性的现行方案是一项比较Rituxan单药治疗与Rituxan和放射性标记单克隆抗体治疗的随机化研究。 它仅限于血小板计数超过150，000的患者。拟定研究IDEC 106-05是一项在血小板计数100- 150，000的患者中使用Rituxan和IDEC Y2 B8的非随机化研究。